Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Buy
53
MNKD Quote, Financials, Valuation and Earnings
Last price:
$5.23
Seasonality move
:
8.26%
Day range:
$5.16 - $5.23
52-week range:
$3.97 - $7.63
Dividend yield:
0%
P/E ratio:
52.20x
P/S ratio:
5.36x
P/B ratio:
--
Volume:
2.5M
Avg. volume:
2.1M
1-year change:
9.66%
Market cap:
$1.6B
Revenue:
$285.5M
EPS (TTM):
$0.10
Analysts' Opinion
-
Consensus RatingMannKind has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.00, MannKind has an estimated upside of 91.57% from its current price of $5.22.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing -72.41% downside risk from its current price of $5.22.
Fair Value
-
According to the consensus of 5 analysts, MannKind has 91.57% upside to fair value with a price target of $10.00 per share.
MNKD vs. S&P 500
-
Over the past 5 trading days, MannKind has underperformed the S&P 500 by -0.12% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
MannKind does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MannKind has grown year-over-year revenues for 10 quarters straight. In the most recent quarter MannKind reported revenues of $76.8M.
Earnings Growth
-
MannKind has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MannKind reported earnings per share of $0.03.
Enterprise value:
1.4B
EV / Invested capital:
-33.29x
Price / LTM sales:
5.36x
EV / EBIT:
20.78x
EV / Revenue:
4.99x
PEG ratio (5yr expected):
--
EV / Free cash flow:
43.38x
Price / Operating cash flow:
46.67x
Enterprise value / EBITDA:
18.36x
Gross Profit (TTM):
$208.9M
Return On Assets:
6.11%
Net Income Margin (TTM):
9.66%
Return On Equity:
--
Return On Invested Capital:
408.64%
Operating Margin:
28.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $99.8M | $199M | $285.5M | $58.5M | $76.8M | |
| Gross Profit | $42.3M | $136.2M | $208.9M | $40.4M | $57.2M | |
| Operating Income | -$68.9M | $10.6M | $68.7M | $10.6M | $22.1M | |
| EBITDA | -$56.3M | $20.6M | $77.5M | $9.9M | $18.6M | |
| Diluted EPS | -$0.34 | -$0.04 | $0.10 | $0.01 | $0.03 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $79.5M | $219.5M | $234.9M | $373.4M | $268.3M | |
| Total Assets | $108.6M | $321.2M | $295.3M | $475.2M | $393.8M | |
| Current Liabilities | $73.7M | $48.3M | $67.3M | $104.1M | $81.8M | |
| Total Liabilities | $289M | $530.5M | $545.8M | $721.4M | $472.7M | |
| Total Equity | -$180.4M | -$209.3M | -$250.5M | -$246.2M | -$78.8M | |
| Total Debt | $122.2M | $281.2M | $273.5M | $268.7M | $36.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$80.7M | $34.1M | $42.5M | $21.7M | $22.6M | |
| Cash From Investing | $4.9M | -$2M | -$96.6M | -$7.9M | $48.2M | |
| Cash From Financing | $21.4M | $136.6M | -$137.3M | $141.7M | -$86.9M | |
| Free Cash Flow | -$88.3M | -$8.3M | $32.8M | $15.8M | $19.7M | |
MNKD
Sector
Market Cap
$1.6B
$39.2M
Price % of 52-Week High
68.41%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
2.44%
-0.81%
1-Year Price Total Return
9.66%
-38.63%
Beta (5-Year)
1.266
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$5.23
200-day SMA
Sell
Level
$5.94
Bollinger Bands (100)
Sell
Level
5.53 - 6.87
Chaikin Money Flow
Sell
Level
-509.8M
20-day SMA
Sell
Level
$5.27
Relative Strength Index (RSI14)
Sell
Level
43.90
ADX Line
Sell
Level
19.62
Williams %R
Neutral
Level
-32.8358
50-day SMA
Sell
Level
$5.63
MACD (12, 26)
Sell
Level
-0.12
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
94.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-7.0417)
Sell
CA Score
(Annual)
Level (-3.5093)
Sell
Beneish M-Score
(Annual)
Level (-1.2881)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.5625)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Stock Forecast FAQ
In the current month, MNKD has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MNKD average analyst price target in the past 3 months is $10.00.
-
Where Will MannKind Stock Be In 1 Year?
According to analysts, the consensus estimate is that MannKind share price will rise to $10.00 per share over the next 12 months.
-
What Do Analysts Say About MannKind?
Analysts are divided on their view about MannKind share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MannKind is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is MannKind's Price Target?
The price target for MannKind over the next 1-year time period is forecast to be $10.00 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MNKD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MannKind is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MNKD?
You can purchase shares of MannKind via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MannKind shares.
-
What Is The MannKind Share Price Today?
MannKind was last trading at $5.23 per share. This represents the most recent stock quote for MannKind. Yesterday, MannKind closed at $5.22 per share.
-
How To Buy MannKind Stock Online?
In order to purchase MannKind stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
